Shimadzu Corporation, a leader in the development of advanced technologies
with a distinguished history of innovation built on the foundation of
contributing to society through science and technology,
has
released a new aggregates sizer aggregation analysis system for
biopharmaceuticals that will enable evaluation of sub-visible
particle (SVP) aggregates that are 100
nm to 10 µm in size.
This new technology allows for the evaluation of the
concentration (µg/mL) of aggregates that can cause shock symptom or
other side effects; thus, it is ideal for quality control and for
improving the efficiency of biopharmaceutical development. The system
is an improvement on Shimadzu's previous SALD series particle size
analyzers, as the Aggregates sizer is over ten times more sensitive.
Moreover,
Shimadzu's new system is more significantly costs-and-time-saving,
for it allows samples to be evaluated for aggregation at the early
stages of biopharmaceutical development. It also allows
aggregation-prone proteins to be screened and eliminated in advance.
Main features of this
new product are the following:
- Quantitatively evaluates SVP range aggregate concentrations
- Measures aggregates with sensitivity 10 times higher than previous particle size analyzers
- Quantitatively evaluates aggregation processes at intervals as short as one second
View Shimadzu jobs at DiversityWorking, the largest job board online, and start a fulfilling career with a trusted diversity company.
No comments:
Post a Comment